Chugai Pharmabody Research
Chang Yu Jing is a Senior Research Associate at Chugai Pharmabody Research since October 2020, where responsibilities include managing daily operations of research projects, troubleshooting results, and mentoring junior research associates. Previously, Chang held positions as a Research Associate, focusing on outsourcing Sanger Sequencing services and onboarding new hires, and as a Research Assistant, demonstrating expertise in antibody mutagenesis and molecular cloning. Prior experience includes a Research Intern role at the National University Health System, conducting a scoping review on cancer screenings and gathering data for a colorectal cancer study. Academic qualifications include an Honours degree in Life Sciences and a minor in Public Health from the National University of Singapore, and currently pursuing a Bachelor of Science in Biology at the University of North Carolina at Chapel Hill.
This person is not in any offices
Chugai Pharmabody Research
1 followers
In the global medical field, there are many diseases in which there are no drug or current drugs are insufficient to address the medical needs of patients. Chugai Pharmabody Research (CPR) is a subsidiary company of Chugai Pharmaceutical in Japan, a member of Roche group, and is committed to address these unmet needs by specializing in the field of antibody drug discovery utilizing proprietary antibody engineering technologies.